MedPath

Time-effect of FEST+TST in the Upper-extremity Rehabilitation of Individuals with Traumatic SCI

Not Applicable
Not yet recruiting
Conditions
Spinal Cord Injuries
Interventions
Other: FES Therapy combined with task-specific training (FEST+TST)
Registration Number
NCT04910204
Lead Sponsor
University Health Network, Toronto
Brief Summary

The purpose of this study is to investigate whether the timing of delivery of functional electrical stimulation therapy in combination with task-specific training (FEST+TST) following spinal cord injury (SCI) influences functional and neurological recovery.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
18
Inclusion Criteria

• Subacute stage (<3 months) after traumatic, motor incomplete (AIS C or D), cervical SCI

Read More
Exclusion Criteria
  • Contraindications for neurophysiological tests
  • Contraindications for FEST
  • Medical conditions that can limit treatment protocols
  • Other neurological diseases (i.e. peripheral neuropathies)
  • Significant persisting mental illness;
  • Learning disabilities;
  • Substance abuse over 6 months prior to recruitment;
  • Hearing and visual deficits sufficient to affect test performance;
  • Contraindication to MRI scanning
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Delayed FEST + TSTFES Therapy combined with task-specific training (FEST+TST)Participants will receive FEST+TST at 6 to 9 months from SCI onset.
Early FEST + TSTFES Therapy combined with task-specific training (FEST+TST)Participants will receive FEST+TST at 3 to 6 months from SCI onset.
Primary Outcome Measures
NameTimeMethod
Spinal Cord Independence Measure (SCIM)Change from baseline SCIM at 3 & 6 months

Self-care SCIM subscore (0-20) and total SCIM score (0-100) will be used to assess the degree of disability for individuals with SCI with respect to activities of daily living; higher scores reflect greater degree of functional independence

American Spinal Injury Association (ASIA) Upper-Extremity Motor Score (UEMS)Change from baseline ASIA UEMS score at 3 & 6 months (ASIA UEMS varies from 0 [complete tetraplegia) to 50 [normal])

International Standards for Neurological Classification of SCI (ISNCSCI) motor and sensory subscores will be used to evaluate degree of impairment.

Graded Redefined Assessment of Strength Sensibility and Prehension (GRASSP)Change from baseline GRASSP score at 3 & 6 months (GRASSP score varies from o (complete paralysis) to 148 [normal])

The GRASSP is a clinical measure used to evaluate upper limb impairment following SCI across 3 domains: strength, sensation, and prehension.

ASIA Upper-Extremity Sensory Score (UESS)Change from baseline ASIA UESS score at 3 & 6 months (ASIA UEMS varies from 0 [complete paralysis) to 50 [normal])

International Standards for Neurological Classification of SCI (ISNCSCI) motor and sensory subscores will be used to evaluate degree of impairment.

Secondary Outcome Measures
NameTimeMethod
Repetitive Nerve StimulationChange in baseline neuromuscular junction transmission at 3 & 6 months

Stimulation of the median nerve (and ulnar nerve) in the dominant (or weaker) upper extremity of each individual will be applied using a bar electrode with the responses recorded in the abductor pollicis brevis (APB) muscle (and first dorsal interosseous muscle).

Laboratorial Assessments (BDNF)Change in baseline BDNF at 3 & 6 months

Blood will be drawn to quantify the presence of brain derived neurotrophic factor \[BDNF\] in the blood.

Needle ElectromyographyChange in baseline EMG activity at 3 & 6 months

Disposable monopolar needles will be used to record the insertional activity, spontaneous activity (at rest) and motor unit action potentials (MUAPs) in selected distal muscles (i.e. abductor pollicis brevis and first dorsal interosseous muscles) and proximal muscles (i.e. pronator teres and flexor carpi ulnaris muscles) that are innervated by median and ulnar nerves, respectively, in the dominant (or weaker) upper extremity of each participant.

F-WaveChange in baseline F-wave amplitude at 3 & 6 months

Percutaneous supramaximal stimulation will be applied distally to the median nerve (and ulnar nerve) in the dominant (or weaker) upper extremity of each individual with responses recorded from the abductor pollicis brevis muscle (and abductor digiti minimi muscle).

Nerve Conduction StudiesChange in baseline nerve conduction at 3 & 6 months

Supramaximal stimulation will be applied to the dominant (or weaker) upper extremity of each participant to determine the amplitude, distal latency and conduction velocity from the median and ulnar motor responses.

H-ReflexChange in baseline H-reflex amplitude at 3 & 6 months

Percutaneous stimulation will be applied to the median nerve of the dominant (or weaker) upper extremity of each individual with responses recorded from the flexor carpi radialis (FCR) muscle using surface electrodes.

Somatosensory Evoked Potentials (SSEPs)Change in baseline SSEPs at 3 & 6 months

Electrical stimulation will be applied to the median nerve (and ulnar nerve) in the distal portion of the dominant (or weaker) upper extremity. Recordings will be obtained from the contralateral C3/C4-Fz sites (based in the international 10/20 system) using surface electrodes.

Motor Evoked Potentials (MEPs)Change in baseline MEPs at 3 & 6 months

Transcranial magnetic stimulation (TMS) will be used to evoke MEPs in the abductor pollicis brevis muscle (and first dorsal interosseous muscle) of the dominant (or weaker) upper extremity with the coil positioned over the contralateral motor cortex.

Functional Magnetic Resonance Imaging (fMRI)Change in baseline functional connectivity at 3 & 6 months

Functional connectivity changes in the motor and somatosensory cortices and pathways will be examined using resting-state fMRI.

Laboratorial Assessments (NTF-3)Change in baseline NTF-3 at 3 & 6 months

Blood will be drawn to quantify the presence of neurotrophic factor 3 \[NTF-3\] in the blood.

Trial Locations

Locations (1)

Lyndhurst Centre, KITE - TRI UHN

🇨🇦

Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath